RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia

Leuk Res. 2021 Dec:111:106735. doi: 10.1016/j.leukres.2021.106735. Epub 2021 Oct 23.

¹ Division of Medical Oncology and Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address: signy.chow@sunnybrook.ca.
² Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada.
³ Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, Toronto, Canada.
⁴ Laboratory Medicine Program, Toronto General Hospital, University Health Network, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
⁵ Division of Hematological Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada.
⁶ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Division of Hematological Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada.

No abstract available

Publication types